Bioverativ (Bioverativ) Net Issuance of Preferred Stock : $0 Mil (TTM As of Dec. 2017)

View and export this data going back to 2017. Start your Free Trial

What is Bioverativ Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Bioverativ's net issuance of preferred for the three months ended in Dec. 2017 was $0 Mil. The number is 0, which means that Bioverativ has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Bioverativ's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2017 was $0 Mil.

Bioverativ Net Issuance of Preferred Stock Historical Data

The historical data trend for Bioverativ's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioverativ Net Issuance of Preferred Stock Chart

Bioverativ Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Net Issuance of Preferred Stock

Bioverativ Quarterly Data
	Dec13	Dec14	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
Net Issuance of Preferred Stock	Get a 7-Day Free Trial							-	-	-	-	-

Bioverativ Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Bioverativ Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Bioverativ's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioverativ (Bioverativ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioverativ Inc (NAS:BIVV) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.bioverativ.com

Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Brian S Posner	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Cox	director, officer: Chief Executive Officer	C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
John Greene	officer: EVP, CFO and Treasurer	51 LIME STREET, LONDON X0 EC3M 7DQ
Geno J Germano	director	5 GIRALDA FARMS, MADISON NJ 07940
Louis J Paglia	director	C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Diantha Duvall	officer: Chief Accounting Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Vivaldi Coelho Rogerio	officer: EVP, Chief Global Therapeutics	225 SECOND AVENUE, WALTHAM MA 02451
Harris Timothy J.r.	officer: EVP, R & D	C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451
Lucia Celona	officer: EVP, HR & Corp Commun. Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Richard Brudnick	officer: EVP, Business Development	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142

Bioverativ (Bioverativ) Headlines

From GuruFocus

Jeff Ubben Buys 1, Sells 1 in 1st Quarter

By Sydnee Gatewood Sydnee Gatewood • 05-24-2017

5 Companies Hit 52-Week Highs

By yifan900 yifan900 • 05-29-2018

Seeking Value in Biotech: Bioverativ

By Mark Yu Mark Yu • 06-29-2017